Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q1 2022 · 10-Q
Revenue$5.24M$5.24M+1,239.4% vs Q1 2021 Net Income-$7.09M-$7.09MN/M vs Q1 2021 EPS Diluted-$0.04-$0.04N/M vs Q1 2021 Gross Profit$5,061,000+1,714.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flow$21,904,000N/M Free Cash Flowderived$21,858,000N/M Margins · derivedGross margin96.6%+25.3 pt vs Q1 2021
Operating margin-122.1%+1680.9 pt vs Q1 2021
Net margin-135.3%+226.8 pt vs Q1 2021
ended Mar 31, 2022 · filed May 12, 2022 · 42 d after period end